Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pyridinic analog of the natural product (-)-spectaline as potential adjuvant for the treatment of central nervous system disorders

Full text
Author(s):
Valli, Marilia [1] ; Betti, Andresa Heemann [2] ; Danuello, Amanda [3] ; Pivatto, Marcos [4] ; Centuriao, Fernanda [2] ; Antonio, Camila Boque [2] ; Kuze Rates, Stela Maris [2] ; Bolzani, Vanderlan da Silva [1]
Total Authors: 8
Affiliation:
[1] Univ Estadual Paulista, Dept Quim Organ, Nucleo Biossintese Bioensaios & Ecofisiol Prod Na, Inst Quim, Araraquara - Brazil
[2] Univ Fed Rio Grande do Sul, Lab Psicofarmacol Expt, Fac Farm, Porto Alegre, RS - Brazil
[3] Univ Fed Triangulo Mineiro, Dept Quim, Inst Ciencias Exatas Nat & Educ, Uberaba - Brazil
[4] Univ Fed Uberlandia, Inst Quim, BR-38400 Uberlandia, MG - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Bioorganic & Medicinal Chemistry Letters; v. 25, n. 10, p. 2247-2250, MAY 15 2015.
Web of Science Citations: 1
Abstract

Previously we designed a series of pyridinic anticholinesterasic compounds based on molecular hybridization between tacrine and the natural piperidine alkaloid (-)-3-O-acetylspectaline isolated from Senna spectabilis. Based on the information that the cholinergic system has an important role in the treatment of schizophrenia and depression, we herein report the evaluation of a series of pyridinic compounds in animal models for antipsychotic and antidepressant-like activities. Compound 2 decreased the immobility time of mice in the forced swimming test (5 and 10 mg/kg p.o.) and prevented the climbing behavior induced by apomorphine (10 mg/kg, p.o.), without impairing animals locomotor activity. (C) 2015 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 03/02176-7 - Conservation and sustainable use of the diversity from Cerrado and Atlantic Forest: chemical diversity and prospecting for potential drugs - phase II
Grantee:Vanderlan da Silva Bolzani
Support Opportunities: BIOTA-FAPESP Program - Thematic Grants
FAPESP's process: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery
Grantee:Glaucius Oliva
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC